Several studies of MBC with PI3K inhibitors or other mutation-directed therapies have now shown that cfDNA testing provides a predictive value of response to treatment at least as reliable as that provided with tumor analysis1,2,5,23. This evidence concerns the gene PIK3CA and neoplasm.